RRC ID 88201
Author Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI.
Title PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Journal Blood
Abstract CD4+Foxp3+ regulatory T cells (Tregs) play a central role in the maintenance of immune tolerance after hematopoietic stem cell transplantation. We previously reported that low-dose interleukin-2 (IL-2) therapy increased circulating Tregs and improved clinical symptoms of chronic graft-versus-host-disease (cGVHD); however, the mechanisms that regulate Treg homeostasis during IL-2 therapy have not been well studied. To elucidate these regulatory mechanisms, we examined the role of inhibitory coreceptors on Tregs during IL-2 therapy in a murine model and in patients with cGVHD. Murine studies demonstrated that low-dose IL-2 selectively increased Tregs and simultaneously enhanced the expression of programmed cell death 1 (PD-1), especially on CD44+CD62L+ central-memory Tregs, whereas expression of other inhibitory molecules, including CTLA-4, LAG-3, and TIM-3 remained stable. PD-1-deficient Tregs showed rapid Stat5 phosphorylation and proliferation soon after IL-2 initiation, but thereafter Tregs became proapoptotic with higher Fas and lower Bcl-2 expression. As a result, the positive impact of IL-2 on Tregs was completely abolished, and Treg levels returned to baseline despite continued IL-2 administration. We also examined circulating Tregs from patients with cGVHD who were receiving low-dose IL-2 and found that IL-2-induced Treg proliferation was promptly followed by increased PD-1 expression on central-memory Tregs. Notably, clinical improvement of GVHD was associated with increased levels of PD-1 on Tregs, suggesting that the PD-1 pathway supports Treg-mediated tolerance. These studies indicate that PD-1 is a critical homeostatic regulator for Tregs by modulating proliferation and apoptosis during IL-2 therapy. Our findings will facilitate the development of therapeutic strategies that modulate Treg homeostasis to promote immune tolerance.
Volume 129(15)
Pages 2186-2197
Published 2017-4-13
DOI 10.1182/blood-2016-09-741629
PII S0006-4971(20)33495-9
PMID 28151427
PMC PMC5391624
MeSH Animals Antigens, CD / genetics Antigens, CD / immunology CTLA-4 Antigen / genetics CTLA-4 Antigen / immunology Chronic Disease Disease Models, Animal Graft vs Host Disease / drug therapy* Graft vs Host Disease / genetics Graft vs Host Disease / immunology* Graft vs Host Disease / pathology Hepatitis A Virus Cellular Receptor 2 / genetics Hepatitis A Virus Cellular Receptor 2 / immunology Immunologic Memory / drug effects* Interleukin-2 / pharmacology* Lymphocyte Activation Gene 3 Protein Mice Mice, Knockout Phosphorylation / drug effects Phosphorylation / genetics Phosphorylation / immunology Programmed Cell Death 1 Receptor / genetics Programmed Cell Death 1 Receptor / immunology* Proto-Oncogene Proteins c-bcl-2 / genetics Proto-Oncogene Proteins c-bcl-2 / immunology STAT5 Transcription Factor / genetics STAT5 Transcription Factor / immunology T-Lymphocytes, Regulatory / immunology* T-Lymphocytes, Regulatory / pathology fas Receptor / genetics fas Receptor / immunology
IF 17.794
Resource
Mice RBRC00904